June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Safety and Efficacy of Risuteganib in Intermediate Non-exudative Age-Related Macular Degeneration
Author Affiliations & Notes
  • Raj Maturi
    Midwest Eye Institute, Indianapolis, Indiana, United States
    Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Glenn J Jaffe
    Duke Eye Center, Durham, North Carolina, United States
  • Justis P Ehlers
    Cole Eye Institute, Cleveland, Ohio, United States
  • Peter K Kaiser
    Cole Eye Institute, Cleveland, Ohio, United States
  • David S Boyer
    Retina Vitreous Associates Medical Group, Los Angeles, California, United States
  • Jeffrey S Heier
    Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
  • Julia A Kornfield
    Caltech, Pasadena, California, United States
  • Baruch D Kuppermann
    University of California, Irvine, Irvine, California, United States
  • Hugo Quiroz-Mercado
    Asociacion para Evitar la Ceguera en Mexico, Mexico City, Mexico
  • Janine Aubel
    Allegro Ophthalmics, San Juan Capistrano, California, United States
  • Lisa Karageozian
    Allegro Ophthalmics, San Juan Capistrano, California, United States
  • Vicken H Karageozian
    Allegro Ophthalmics, San Juan Capistrano, California, United States
  • Melvin Sarayba
    Allegro Ophthalmics, San Juan Capistrano, California, United States
  • Footnotes
    Commercial Relationships   Raj Maturi, Aerpio (F), Allegro Ophthalmics (C), Allegro Ophthalmics (R), Allegro Ophthalmics (F), Allergan (F), Astellas Pharma (F), Boehringer Ingelheim Pharma GmbH (F), Genentech (F), Glaxosmithkline (F), Graybug (F), Graybug (C), Graybug (R), Gyroscope Therapeutics (F), Kalvista (F), MedEdicus (C), MedEdicus (R), Neurotech USA (C), Neurotech USA (R), Oxurion NV (F), Roche/Genentech (F), Samsung Bioepsis (F), Santen (F), Santen (C), Santen (R); Glenn Jaffe, Acucela (C), Clearside (C), EyePoint (C), Graybug (C), Neurotech (C), Novartis (C); Justis Ehlers, Aerpio (C), Aerpio (R), Alcon (C), Alcon (R), Alimera Sciences (C), Allegro Ophthalmics (C), Allergan (C), Allergan (R), Boerhinger Ingelheim (R), Genentech (C), Genentech (R), Leica (C), Leica (P), Novartis (C), Novartis (R), Regeneron (C), Regeneron (R), Roche (C), Santen (C), Thrombogenics (C), Thrombogenics (R), Zeiss (C); Peter Kaiser, Aerie (C), Aerpio (C), Alcon (C), Allegro Ophthalmics (C), Allegro Ophthalmics (I), Allergan (C), Annexon (C), Bausch+Lomb (C), Bayer (C), BioEg GmbH (C), Biogen Idec (C), Boerenger Ingelheim (C), Carl Zeiss Medtec (C), Clearside Biomedical (C), Clearside Biomedical (I), Eyevensys (C), Galecto (C), Galimedix (C), Glaukos (C), iRenix (C), jCyte (C), Kanghong Biotech (C), Kodiak (C), NGM Biopharmaceuticals (C), Novartis (C); David Boyer, Aerpio (C), Aerpio (F), Allegro Ophthalmics (C), Allegro Ophthalmics (I), Allergan (C), Bayer (C), Genentech (C), Genentech (F), Novartis (C), Novartis (F), Regeneron (C), Regeneron (F), Roche (C), Santen (C); Jeffrey Heier, Adverum (C), Adverum (I), Aerie (C), Aerie (F), Aerpio (C), Aerpio (F), Aldeyra (C), Allegro Ophthalmics (C), Allegro Ophthalmics (I), Allergan (C), Annexon (C), Apellis (C), Apellis (F), Array (C), Asclepix (C), Eloxx (C), Galimedix (C), Genentech (C), Genentech/Roche (F), Generation Bio (C), Gyroscope (C), jCyte (C), jCyte (I), Ocular Therapeutix (C), Ocular Therapeutix (I); Julia Kornfield, Allegro Ophthalmics (I), Allegro Ophthalmics (F); Baruch Kuppermann, Alimera Sciences (C), Allegro Ophthalmics (C), Allegro Ophthalmics (I), Allegro Ophthalmics (F), Allegro Ophthalmics (R), Allergan (F), Allergan (C), Allergan (R), Apellis (F), Cell Care Therapeutics (C), Cell Care Therapeutics (I), Dose Medical Corporation (C), Eyedaptic (C), Eyedaptic (I), Genentech (F), Genentech (C), Ionis (F), jCyte (F), jCyte (C), jCyte (I), Novartis (F), Novartis (C), Novartis (R), Regeneron (F), Regeneron (C); Hugo Quiroz-Mercado, Allegro Ophthalmics (C), Allegro Ophthalmics (I), Allegro Ophthalmics (F); Janine Aubel, Allegro Ophthalmics (E), Allegro Ophthalmics (I); Lisa Karageozian, Allegro Ophthalmics (E), Allegro Ophthalmics (I); Vicken Karageozian, Allegro Ophthalmics (E), Allegro Ophthalmics (I); Melvin Sarayba, Allegro Ophthalmics (E), Allegro Ophthalmics (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 1944. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Raj Maturi, Glenn J Jaffe, Justis P Ehlers, Peter K Kaiser, David S Boyer, Jeffrey S Heier, Julia A Kornfield, Baruch D Kuppermann, Hugo Quiroz-Mercado, Janine Aubel, Lisa Karageozian, Vicken H Karageozian, Melvin Sarayba; Safety and Efficacy of Risuteganib in Intermediate Non-exudative Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2020;61(7):1944.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Risuteganib is a small synthetic peptide that regulates select integrin functions involved in the pathogenesis of dry age-related macular degeneration (AMD). This study evaluated the safety and efficay of risuteganib for the treatment of dry AMD.

Methods : Randomized, double-masked, placebo-controlled Phase 2 study in eyes with intermediate dry AMD presenting with best-corrected visual acuity (BCVA) between 20/40-20/200 was conducted across multiple centers in the United States. Patients were randomized to receive either intravitreal 1.0mg risuteganib or sham injection at baseline. At week 16, patients in the risuteganib group received a second dose and the sham group crossed over and receive a single dose of 1.0mg risuteganib. The primary endpoint was the percentage of population with ≥ 8 letters BCVA gain from baseline to week 28 in 1.0mg risuteganib vs baseline to week 12 for sham.

Results : Forty-five patients were enrolled in the study. At baseline, mean patient age was 78.8 and 75.9 years and mean baseline BCVA was 67.1 and 64.4 letters in the sham and risuteganib groups, respectively. The primary endpoint was met; 48% of patients in the risuteganib group at week 28 and 7% of patients in the sham group at week 12 gained > 8 letters from baseline (p=0.013). Of the risuteganib treated patients, 20% gained > 15 letters at week 28; no patients in the sham group at week 12 had this gain. On a post-hoc masked analysis by 2 independent reading centers, greater outer retinal and photoreceptor thickness and volume and smaller ellipsoid zone defect area in the central 1 mm zone at baseline were associated with increased BCVA response to risuteganib. Risuteganib demonstrated a good safety profile in this study.

Conclusions : Risuteganib showed significant benefit over sham in patients with dry AMD with respect to proportion of patients gaining > 8 letters of BCVA from baseline. Furthermore, post hoc analysis provides preliminary insights into baseline anatomic features that may help to determine likelihood of BCVA response to risuteganib. These findings will be confirmed in an upcoming larger trial.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×